<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720391</url>
  </required_header>
  <id_info>
    <org_study_id>IEO 1436</org_study_id>
    <nct_id>NCT04720391</nct_id>
  </id_info>
  <brief_title>Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)</brief_title>
  <acronym>MONET</acronym>
  <official_title>Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective/prospective observational multicentric trial on patients with bone&#xD;
      metastases from NENs.&#xD;
&#xD;
      General objectives:&#xD;
&#xD;
        -  To trace on a national scale the frequency of bone metastases in patients with&#xD;
           neuroendocrine neoplasm (NEN) and their clinical management.&#xD;
&#xD;
        -  To correlate clinical and biological factors to clinical outcomes.&#xD;
&#xD;
        -  To centralise and to make homogeneous clinical, pathological, instrumental and&#xD;
           therapeutic information.&#xD;
&#xD;
        -  To set up a database and to acquire biological material for studying predictive and&#xD;
           prognostic biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background, rationale and objectives:&#xD;
&#xD;
      On March 25th 2015 the Ethical Committee from IEO approved the academic study entitled &quot;Bone&#xD;
      metastases in neuroendocrine tumors (NETs): a survey on natural history, prognostic value and&#xD;
      treatment approach&quot;, version 1.0 30-Jan-2015. This was a retrospective study led to report&#xD;
      how the issue bone metastases from NETs was handle in real practice. Preliminary data related&#xD;
      to 321 patients from 18 Italian centers were presented as a poster at the ESMO 2017 congress&#xD;
      (Fazio et al. 448P) and they will be included in a manuscript to submit for publication in a&#xD;
      peer-review journal. The current protocol regards the continuation of the retrospective&#xD;
      analysis, starting since 2014, since the previous study required data collection up to 2013,&#xD;
      and at the same time a multicenter prospective observational analysis on the topic.&#xD;
&#xD;
      Duration of the study The study will regard patients fulfilling the eligibility criteria from&#xD;
      2014 to 2021. Data analysis will be completed by the year 2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>Overall survival (OS) will be calculated from the date of BM diagnosis to the date of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of skeletal related events (SRE) on survival</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>Influence of skeletal related events (SRE) on overall survival (OS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To evaluate the correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of the use of bisphosphonates or RANK-ligands</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To evaluate the influence of the use of bisphosphonates or RANK-ligands on overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation from bone metastases and age, gender, primary site, Ki-67, grade of differentiation</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To evaluate the correlation between bone metastases and patients and tumor's features</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural history (time between diagnosis of NEN and first diagnosis of bone metastasis, frequency and time to SRE, sites of bone metastases)</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To describe the natural history time between diagnosis of NEN and first diagnosis of bone metastasis, frequency and time to SRE, sites of bone metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological diagnosis (CT, MRI)</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To describe the morphological features of bone metastases in patients with NEN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional diagnosis (68GaPET/CT-DOTA-peptide, 18FDGPET/CT)</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To To describe the functional features of bone metastases in patients with NEN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of antitumor therapy on bone metastases behavior</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To describe the global impact of antitumor therapies on bone metastases behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of supportive care</measure>
    <time_frame>01/2021 - 12/2021</time_frame>
    <description>To describe the global impact of supportive care on overal survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bone Metastases</condition>
  <condition>Neuroendocrine Neoplasm</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bone metastases from NENs histologically proved.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of NEN&#xD;
&#xD;
          -  Instrumental and/or histological diagnosis of bone metastasis&#xD;
&#xD;
          -  At least one year of follow-up from the diagnosis of bone metastasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Small cell lung carcinoma&#xD;
&#xD;
          -  MiNEN&#xD;
&#xD;
          -  Non neuroendocrine neoplasm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Fazio, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology, IEO, IRCCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Spada, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology, IEO, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darina Tamayo, PharmSc.</last_name>
    <phone>+39(0)294372686</phone>
    <email>darina.tamayo@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Mazzon, Ph.D.</last_name>
    <phone>+39(0)294372686</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Institute of Oncology, IEO, IRCCS</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darina Tamayo, PharmSc.</last_name>
      <phone>+39(0)294372686</phone>
      <email>darina.tamayo@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Cristina Mazzon, Ph.D.</last_name>
      <phone>+39(0)294372686</phone>
      <email>cristina.mazzon@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alice Laffi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manila Rubino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.</citation>
    <PMID>29295881</PMID>
  </results_reference>
  <results_reference>
    <citation>Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoldi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS One. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019.</citation>
    <PMID>30893350</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NET</keyword>
  <keyword>NEC</keyword>
  <keyword>Neuroendocrine tumors</keyword>
  <keyword>Neuroendocrine carcinomas</keyword>
  <keyword>Bisphosphonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

